 |
Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase |
|---|---|
| Trade Name | |
| Orphan Indication | Myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis) |
| USA Market Approval | USA |
| USA Designation Date | 2011-03-03 00:00:00 |
| Sponsor | Eli Lilly and Company;Lilly Corporate Center;Indianapolis, Indiana, 46285 |
